CoChat
Sign Up
Cited by 367Protein Structure and DynamicsProtein Kinase Regulation and GTPase SignalingEnzyme Structure and Function

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Defining a new nomenclature for the structures of active and inactive kinases

Open access
Modi, Vivek, Dunbrack, Roland L.·2019·Proceedings of the National Academy of Sciences
DOI 10.1073/pnas.1814279116PMC PMC6452665

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Targeting protein kinases is an important strategy for intervention in cancer. Inhibitors are directed at the active conformation or a variety of inactive conformations. While attempts have been made to classify these conformations, a structurally rigorous catalog of states has not been achieved. The kinase activation loop is crucial for catalysis and begins with the conserved DFGmotif. This motif is observed in two major classes of conformations, DFGin—a set of active and inactive conformations where the Phe residue is in contact with the C-helix of the N-terminal lobe—and DFGout—an inactive form where Phe occupies the ATP site exposing the C-helix pocket. We have developed a clustering of kinase conformations based on the location of the Phe side chain (DFGin, DFGout, and DFGinter or intermediate) and the backbone dihedral angles of the sequence X-D-F, where X is the residue before the DFGmotif, and the DFG-Phe side-chain rotamer, utilizing a density-based clustering algorithm. We have identified eight distinct conformations and labeled them based on the Ramachandran regions (A, alpha; B, beta; L, left) of the XDF motif and the Phe rotamer (minus, plus, trans). Our clustering divides the DFGin group into six clusters including BLAminus, which contains active structures, and two common inactive forms, BLBplus and ABAminus. DFGout structures are predominantly in the BBAminus conformation, which is essentially required for binding type II inhibitors. The inactive conformations have specific features that make them unable to bind ATP, magnesium, and/or substrates. Our structurally intuitive nomenclature will aid in understanding the conformational dynamics of kinases and structure-based development of kinase drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1814279116

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Structure of a typical protein kinase domain displaying ATP binding site and conserved elements around it (INSR kinase, PDB ID code 1GAG).
Fig. 1. Structure of a typical protein kinase domain displaying ATP binding site and conserved elements around it (INSR kinase, PDB ID code 1GAG).CC BY-NC-ND · PubMed Central
Fig. 2. Analysis of catalytically primed structures. (A) Catalytically primed structure of insulin receptor kinase (PDB ID code 3BU5) with bound ATP and Mg2+ ion. Important interactions are marked with dashed lines. (B) Ramachandran plot of catalytically primed structures (those with bound ATP and Mg2+, a phosphorylated activation loop, and resolution ≤2.25 Å): X-DFG (residue before the DFGmotif, blue), DFG-Asp (green), DFG-Phe (orange), and DFG-Gly (red). The Ramachandran regions are marked A (alpha), B (beta), L (left), and E (epsilon). (C) Scatterplot of side-chain dihedral angles χ1 and χ2 for DFG-Asp (green) and DFG-Phe (orange) of catalytically primed structures. Asp is in a trans rotamer (χ1 ∼ 180°) and Phe is in a g− rotamer (χ1 ∼ 300° or −60°).
Fig. 2. Analysis of catalytically primed structures. (A) Catalytically primed structure of insulin receptor kinase (PDB ID code 3BU5) with bound ATP and Mg2+ ion. Important interactions are marked with dashed lines. (B) Ramachandran plot of catalytically primed structures (those with bound ATP and Mg2+, a phosphorylated activation loop, and resolution ≤2.25 Å): X-DFG (residue before the DFGmotif, blue), DFG-Asp (green), DFG-Phe (orange), and DFG-Gly (red). The Ramachandran regions are marked A (alpha), B (beta), L (left), and E (epsilon). (C) Scatterplot of side-chain dihedral angles χ1 and χ2 for DFG-Asp (green) and DFG-Phe (orange) of catalytically primed structures. Asp is in a trans rotamer (χ1 ∼ 180°) and Phe is in a g− rotamer (χ1 ∼ 300° or −60°).CC BY-NC-ND · PubMed Central
Fig. 3. Locations of Phe side chain in DFGin, DFGinter, and DFGout structures of kinases. (A) Positions of DFG-Phe side chain in DFGin (cyan), DFGinter (orange), and DFGout (purple) of EGFR. (B) Distances, D1 and D2, used to identify the location of the Phe side chain of the DFGmotif. (C) Scatterplot of D1 and D2. DFGin (cyan), DFGinter (orange), and DFGout (purple) structures identified with hierarchical clustering; catalytically primed structures (cyan triangles) and structures with bound type II inhibitors (purple triangles) are marked.
Fig. 3. Locations of Phe side chain in DFGin, DFGinter, and DFGout structures of kinases. (A) Positions of DFG-Phe side chain in DFGin (cyan), DFGinter (orange), and DFGout (purple) of EGFR. (B) Distances, D1 and D2, used to identify the location of the Phe side chain of the DFGmotif. (C) Scatterplot of D1 and D2. DFGin (cyan), DFGinter (orange), and DFGout (purple) structures identified with hierarchical clustering; catalytically primed structures (cyan triangles) and structures with bound type II inhibitors (purple triangles) are marked.CC BY-NC-ND · PubMed Central
Fig. 4. DBSCAN clustering of dihedral angles that position the DFG-Phe side chain. Clustering was performed on the DFGin, DFGinter, and DFGout groups separately with an angular metric of the backbone dihedral angles of the X-DFG, DFG-Asp, and DFG-Phe residues and the χ1 of DFG-Phe. Clusters are named by the Ramachandran regions of the X-DFG, DFG-Asp, and DFG-Phe residues and the χ1 rotamer of DFG-Phe: g− (χ1 ∼ −60°, minus, magenta); g+ (χ1 ∼ +60°, plus, blue); trans rotamer (χ1 ∼ 180°, trans, green).
Fig. 4. DBSCAN clustering of dihedral angles that position the DFG-Phe side chain. Clustering was performed on the DFGin, DFGinter, and DFGout groups separately with an angular metric of the backbone dihedral angles of the X-DFG, DFG-Asp, and DFG-Phe residues and the χ1 of DFG-Phe. Clusters are named by the Ramachandran regions of the X-DFG, DFG-Asp, and DFG-Phe residues and the χ1 rotamer of DFG-Phe: g− (χ1 ∼ −60°, minus, magenta); g+ (χ1 ∼ +60°, plus, blue); trans rotamer (χ1 ∼ 180°, trans, green).CC BY-NC-ND · PubMed Central
Fig. 5. Structure examples of each cluster. (A) BLAminus; (B) BLAplus; (C) ABAminus; (D) BLBminus; (E) BLBplus; (F) BLBtrans; (G) BBAminus (DFGout); (H) BABtrans (DFGinter).
Fig. 5. Structure examples of each cluster. (A) BLAminus; (B) BLAplus; (C) ABAminus; (D) BLBminus; (E) BLBplus; (F) BLBtrans; (G) BBAminus (DFGout); (H) BABtrans (DFGinter).CC BY-NC-ND · PubMed Central
Fig. 6. Electron densities indicate incorrectly modeled ABAminus structures. (A) Electron density of ABAminus structures consistent with BLAminus structure. 2Fo-Fc (gray); Fo-Fc (green, positive density, indicating density not represented by an atom; red, negative density, indicating density where an atom has been placed without electron density support). PDB ID code 1K3A_A (IGF1R); 4BL1_A (MELK); 3IEC_D (MARK2). (B) Kernel density estimates of the EDIA scores of the backbone carbonyl atom (X_O) of the X-DFG residue for ABAminus (orange) and BLAminus (black) structures. (C) Scatterplot and von Mises kernel regressions of EDIA of X_O vs. χ2 of DFG-Asp of ABAminus (orange) and BLAminus (black) structures. BLAminus structures mostly have χ2 near 0°. ABAminus structures with χ2 near 0° have poor electron density and may be mismodeled BLAminus structures.
Fig. 6. Electron densities indicate incorrectly modeled ABAminus structures. (A) Electron density of ABAminus structures consistent with BLAminus structure. 2Fo-Fc (gray); Fo-Fc (green, positive density, indicating density not represented by an atom; red, negative density, indicating density where an atom has been placed without electron density support). PDB ID code 1K3A_A (IGF1R); 4BL1_A (MELK); 3IEC_D (MARK2). (B) Kernel density estimates of the EDIA scores of the backbone carbonyl atom (X_O) of the X-DFG residue for ABAminus (orange) and BLAminus (black) structures. (C) Scatterplot and von Mises kernel regressions of EDIA of X_O vs. χ2 of DFG-Asp of ABAminus (orange) and BLAminus (black) structures. BLAminus structures mostly have χ2 near 0°. ABAminus structures with χ2 near 0° have poor electron density and may be mismodeled BLAminus structures.CC BY-NC-ND · PubMed Central
Fig. 7. Inhibitors bound to structures in multiple clusters: BLAminus (sky blue), BLAplus (dark green), BLBminus (light gray), BLBplus (light green), BBAminus (purple), BABtrans (orange), DFGout-noise (light purple), and DFGinter-noise (light orange). (A) Sunitinib bound to PAK6, PHKG2, and STK24 in BLAminus; ITK in BLAplus; CDK2 in BLBminus; KIT in BBAminus; KIT in DFGout-noise. (B) Dasatinib bound to ABL1, STK10, and STK24 in BLAminus; BTK in BLAplus; EPHA2 in BLBminus; PTK6 in BLBplus; BMX and BTK in BABtrans; ABL1 in DFGinter-noise; DDR1 in DFGout-noise. (C) Bosutinib bound to EPHA2, PMYT1, SRC in BLAminus; ERBB3 in BLBplus; STK10 in DFGin-noise; ABL1 and KCC2A in DFGinter-noise. (D) Imatinib bound to ABL1, ABL2, CSF1R, DDR1, KIT, and LCK in BBAminus.
Fig. 7. Inhibitors bound to structures in multiple clusters: BLAminus (sky blue), BLAplus (dark green), BLBminus (light gray), BLBplus (light green), BBAminus (purple), BABtrans (orange), DFGout-noise (light purple), and DFGinter-noise (light orange). (A) Sunitinib bound to PAK6, PHKG2, and STK24 in BLAminus; ITK in BLAplus; CDK2 in BLBminus; KIT in BBAminus; KIT in DFGout-noise. (B) Dasatinib bound to ABL1, STK10, and STK24 in BLAminus; BTK in BLAplus; EPHA2 in BLBminus; PTK6 in BLBplus; BMX and BTK in BABtrans; ABL1 in DFGinter-noise; DDR1 in DFGout-noise. (C) Bosutinib bound to EPHA2, PMYT1, SRC in BLAminus; ERBB3 in BLBplus; STK10 in DFGin-noise; ABL1 and KCC2A in DFGinter-noise. (D) Imatinib bound to ABL1, ABL2, CSF1R, DDR1, KIT, and LCK in BBAminus.CC BY-NC-ND · PubMed Central
Fig. 8. The intact regulatory spine of active and inactive structures. (A) Active BLAminus (3BU5_A, INSR); (B) inactive BLAplus (4F64_A, FGFR1); (C) inactive BLBminus (5NK7_A, EPHA2); (D) inactive BLBplus (4UY9_B, M3K9). We consider the spine intact if there is at least one atom–atom contact (≤4.5 Å) between the side chains of each residue of the spine.
Fig. 8. The intact regulatory spine of active and inactive structures. (A) Active BLAminus (3BU5_A, INSR); (B) inactive BLAplus (4F64_A, FGFR1); (C) inactive BLBminus (5NK7_A, EPHA2); (D) inactive BLBplus (4UY9_B, M3K9). We consider the spine intact if there is at least one atom–atom contact (≤4.5 Å) between the side chains of each residue of the spine.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 367

Related

See all

Metadata

Authors
Modi, V., & Dunbrack, R. L.
Affiliations
Fox Chase Cancer Center (US)
Corresponding author
Dunbrack, Roland L.
ORCID
Venue
Proceedings of the National Academy of Sciences
Publisher
National Academy of Sciences
Published
2019-03-13
Volume
116
Issue
14
Pages
6818-6827
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
DOI
10.1073/pnas.1814279116
PMC
PMC6452665
OpenAlex
W2922340164
Cited by
367
References
38
Citations by year
2026: 54 · 2025: 44 · 2024: 65 · 2023: 68 · 2022: 48 · 2021: 48 · 2020: 33 · 2019: 6
FWCI
11.16
Type
journal article
Language
en
Open access
Licence
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
HHS | NIH | National Institute of General Medical Sciences (R35 GM122517)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
Keywords
protein kinases, DFG motif, kinase activation loop, kinase inhibitors, backbone dihedral angles, density-based clustering, structure-based drug design, type II kinase inhibitors
MeSH terms
Algorithms, Models, Molecular, Terminology as Topic, Protein Kinases, Substrate Specificity, Protein Structure, Secondary, Catalytic Domain, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review